This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Chirigos, M. A. Articles by Pryor, J. Search for Related Content PubMed PubMed Citation Articles by Chirigos, M. A. Articles by Pryor, J.

Prolongation of Chemotherapeutically Induced Remission of a Syngeneic Murine Leukemia by L-2,3,5,6-Tetrahydro-6-phenylimidazo[2,1-b]thiazole Hydrochloride

Viral Biology Branch, National Cancer Institute, Bethesda, Maryland 20014

L-2,3,5,6-Tetrahydro-6-phenylimidazo[2,1-b]thiazole hydrochloride (LMS), when used in concert with 1,3-bis(2-chloroethyl)-1-nitrosourea, resulted in a significantly higher percentage of long-term leukemic-free survivors. The additive effect provided by LMS treatment was evident during the immunosuppressed period induced by 1,3-bis(2-chloroethyl)-1-nitrosourea treatment and when tumor load was minimal. Treatment with LMS alone did not appear to possess any significant antitumor effect.

The beneficial effect of LMS treatment may be attributable to the immunostimulatory activity reported for this drug. LMS appears to possess characteristics that make it an excellent candidate for use as an immunostimulant in cancer combined modality treatment.

Received 8/12/74. Accepted 12/30/74.